home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Sapphire Collection
/
Software Vault (Sapphire Collection) (Digital Impact).ISO
/
cdr16
/
med9410e.zip
/
M94B0796.TXT
< prev
next >
Wrap
Text File
|
1994-11-11
|
3KB
|
46 lines
Document 0796
DOCN M94B0796
TI Chemotherapy associated with zidovudine and Gm-CSF in human
immunodeficiency virus-related non-Hodgkin's lymphoma (HIV-NHL) (Meeting
abstract).
DT 9412
AU Gabarre J; Lepage E; Thyss A; Bastion Y; Sebban C; Schlaifer D; Ribrag
V; Fereres M; Raphael M; Gisselbrecht C; GELA, Saint-Louis Hosp., Paris,
France
SO Proc Annu Meet Am Assoc Cancer Res; 35:A1138 1994. Unique Identifier :
AIDSLINE ICDB/94602824
AB HIV-NHL patients have an estimated survival according to authors between
5-9 months, a better survival can be obtained in patients with a good
performance status (PS), CD4 count greater than 100 ul/mm3 and without
AIDS. Main causes of death are lymphoma, opportunistic infections and
therapy toxicity. In order to reduce AIDS-related mortality and maintain
the intended dose of chemotherapy, a phase II study was undertaken using
the intensive induction chemotherapy regimen LNH84 (Am J Med 95:188-96,
1993) with low-dose of zidovudine (5 mg/kg/day) and Gm-CSF (5 ug/kg/day;
Schering-Plough). Thirty-two patients were included and their
characteristics were histology-high grade lymphoma: 19 (15 Burkitt);
intermediate grade: 13; stage III-IV: 19; extranodal sites greater than
or equal to 2: 14 (marrow 5); LDH greater than 1N: 20; PS greater than
or equal to 2: 7; CD4 less than or equal to 100: 12; prior AIDS: 4.
Complete response (CR) occurred in 16 patients (50%) and partial
response in 3, while 7 (22%) died during induction. Intended dose
intensity was greater than 70% in 16 (57%) and less than or equal to 70%
in 12. Six patients had long-lasting hematological toxicity. Among the
16 CR, 5 relapsed. Overall survival was poor (6 months). No reduction of
AIDS mortality was observed. Hematological toxicity of both chemotherapy
and zidovudine is insufficiently reduced with Gm-CSF.
DE Acquired Immunodeficiency Syndrome/*DRUG THERAPY/MORTALITY
Bleomycins/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Combined Modality
Therapy Cyclophosphamide/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS
Dose-Response Relationship, Drug Doxorubicin/ADMINISTRATION &
DOSAGE/ADVERSE EFFECTS Drug Administration Schedule Follow-Up Studies
Granulocyte-Macrophage Colony-Stimulating Factor/*ADMINISTRATION &
DOSAGE/ADVERSE EFFECTS Human Lymphoma, AIDS-Related/*DRUG
THERAPY/MORTALITY Prednisolone/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS
Survival Rate Vindesine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS
Zidovudine/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).